Liang Cheng: NEWEST State-of-the Art -Review on Bladder Cancer Diagnosis and Treatment
Liang Cheng, Professor and Vice Chair for Translational Research at Warren Alpert Medical School of Brown University, shared a post on LinkedIn:
“NEWEST State-of-the Art -Review on Bladder Cancer Diagnosis and Treatment just released this week (BMJ Journal impact factor 107!)
I am exceedingly honored to be invited to work on this commissioned review with my esteemed colleagues, Drs Antonio Lopez-Beltran, Mike Cookson, and Brendan Guercio over the last two years.
Check it out.
The overarching questions remain-
· What are the biomarkers to improve the detection of aggressive NMIBC progressing under standard treatments?
· How can the non-invasive detection of bladder cancer recurrences using molecular urine biomarkers be improved?
· What are the biomarkers that predict improved treatment responses in locally advanced and metastatic bladder cancer (eg, PDL1, PD1, CTLA4, FGFR3, nectin-4, TROP2, molecular subtypes)?
· Can the immune microenvironment be modulated to better potentiate treatments for bladder cancer?”
Source: Liang Cheng/LinkedIn